Summary PurposeIntravitreal ranibizumab or bevacizumab are the most used drugs for treatment of neovascular age-related macular degeneration (nAMD). Repeated intravitreal injections represent an economic burden and may be associated with serious complications. The aim of this study is to evaluate the number of needed injections within 1 year of treatment. Methods55 patients over 50 years of age with nAMD and visual acuity (VA) between 20/40 and 20/320 were included. Scheduled visits and treatment were performed monthly for 1 year. After a loading dose of three intravitreal injections (either ranibizumab = group 1 or bevacizumab = group 2), an “as needed” regimen was performed. Primary endpoint was a difference in the injection frequencies of ranibizumab and bevacizumab. Secondary endpoints were best corrected visual acuity (BCVA) and central retinal thickness (CRT). ResultsDifference in number of injections was not significant (5.00 ± 1.67 (ranibizumab group) vs. 5.80 ± 2.28 (bevacizumab group), p = 0.084). Mean BCVA was 59.12 ± 16.64 letters after 12 months if patients received ranibizumab (p = 0.001) and 64.75 ± 17.03 letters if patients received bevacizumab (p = 0.037). There was no statistical significance between the two groups (p = 0.631). The mean CRT did not differ significantly between groups after 12 months (315.67 ± 65.86 µm for ranibizumab, 350.47 ± 102.84 µm for bevacizumab, p = 0.088). ConclusionThere was no difference in number of treatment, BCVA and CRT after 1 year between ranibizumab and bevacizumab in patients with nAMD.
bevacizumab         1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Bevacizumab           

bevacizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Bevacizumab           

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

nAMD                          0.9999999882406884^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/NAMD                  

loading dose                  0.9999999999995453^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Loading_dose          

intravitreal                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Intravitreal_administration

CRT                           0.9999751614615698^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Cathode_ray_tube      

bevacizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Bevacizumab           

intravitreal                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Intravitreal_administration

nAMD                          0.9999999882406884^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/NAMD                  

age-related macular degeneration1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Macular_degeneration  

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

statistical significance      1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Statistical_significance

CRT                           0.9999751614615698^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Cathode_ray_tube      

visual acuity                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Visual_acuity         

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

frequencies                   0.9997476378396215^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Frequency             

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

nAMD                          0.9999999882406884^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/NAMD                  

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

CRT                           0.9999751614615698^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Cathode_ray_tube      

VA                            0.7375969580931402^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Virginia              

Secondary endpoints           1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/End_point_of_clinical_trials

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

bevacizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Bevacizumab           

neovascular                   0.8679687199313384^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/neovascularization    

bevacizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Bevacizumab           

µm                            0.999997426178781^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Micrometre            

visual acuity                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Visual_acuity         

drugs                         0.8390648216351951^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Drug                  

bevacizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Bevacizumab           

retinal                       0.999999999951001^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Retina                

µm                            0.999997426178781^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Micrometre            

bevacizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Bevacizumab           

